On June 16, Sino Biopharmaceutical fell 3.14% in regular trading, trading at HK$4.63/share, with turnover of approximately HK$115 million.

On the news front, the pharmaceutical sector faced broad-based selling pressure, with peer CSPC Pharmaceutical Group declining 3.54% and Hutchmed falling 2.35%, reflecting continued systemic weakness across the industry. Morgan Stanley recently lowered its target price on the company from HK$8.3 to HK$7.8 while maintaining an Overweight rating. Additionally, the stock's short-selling ratio remained elevated at 24.21%, indicating significant bearish positioning and notable market divergence on the company's outlook.

The company recently announced a HK$2 billion share repurchase plan over the next 12 months and has spent approximately HK$338 million acquiring 60.35 million shares since the start of the year. Despite these supportive measures, sector headwinds and short-seller activity continue to weigh on price action.

Sino Biopharmaceutical Limited is an investment holding company principally engaged in the pharmaceutical business, covering production and sales of modernized Chinese medicine preparations and Western pharmaceuticals, long-term investments, and related healthcare operations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)